CN1190098A - Preparation, medicinal composition and application of grouped gensenoside - Google Patents
Preparation, medicinal composition and application of grouped gensenoside Download PDFInfo
- Publication number
- CN1190098A CN1190098A CN98100070A CN98100070A CN1190098A CN 1190098 A CN1190098 A CN 1190098A CN 98100070 A CN98100070 A CN 98100070A CN 98100070 A CN98100070 A CN 98100070A CN 1190098 A CN1190098 A CN 1190098A
- Authority
- CN
- China
- Prior art keywords
- saponin
- component
- preparation
- alkali metal
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The present invention provides a preparation process of grouped ginsenoside, medicinal composition containing protopanaxyndiol group saponin or protopanaxyntriol group saponin, and the application of the said medicinal composition in preventing and curing pathological change of cell, tissue or organ caused by various reasons. The said preparation process includes dissolving total saponin into lower alcohol solution, precipitation using alkali metal hydroxide as precipitant and separation of precipitate as the first component from the supernatant as the second component.
Description
The present invention relates to prepare the method for ginsenoside of dividing into groups, contain the pharmaceutical composition that protopanoxadiol group saponin or Protopanaxatriol with the preparation of this method organize saponin, and these compositions in prevention and treatment because of nature or chemical mutation, free-radical oxidn damage, or the application in radiotherapy damage or physical damnification such as obstructive the ischemic cell, tissue or the organ pathological change that cause.
Genseng (panax gingseng), Radix Panacis Quinquefolii (panax quinquefolium) and pseudo-ginseng (panaxnotoginseng) etc. all belong to the araliaceae ginseng plant, nearly all part of these plants all contains many kinds of ginsenosides as root, rhizome, flower, fruit and cauline leaf.Closely during the last ten years, the saponin to these panax species has carried out research in depth, and not only content is abundant to find ginsenoside, particularly dammarane type saponin, and has biologic activity very widely.
According to the polar difference of ginsenoside, it can be divided into two big components.In general, based on the silica gel thin-layer chromatography analytical results, wherein the Rf value is the bigger component of polarity below corresponding Re (in the panaxoside monomer a kind of), is called component I; The Rf value at corresponding Re place and above be the less component of polarity, be called component I I.The physiologically active of different components is not quite similar in total saponin, and is that have even opposite fully.Therefore, total saponin of panax species is separated into different components, will helps reasonable development and utilization, and be convenient to further separate and the purifying saponin monomer different components.
Based on the monomer component of the total saponin of panax species, the component I of Radix Ginseng total saponins mainly by ginsenoside-Ro ,-Rb
1,-Rb
2,-Rb
3,-Rc and-several or all monomeric mixtures among the Rd form, component I I then mainly by ginsenoside-Re ,-Rg
1,-Rg
2,-Rg
3,-F
2,-Rf ,-RF
11,-RT
5, and denier-Rh
1And Rh
2In several or all monomeric mixtures form.
If with the total saponin of ginseng is the feedstock production component I, promptly so-called ginseng glycol group saponin can obtain mainly by-Ra
1,-Ra
2,-Ra
3,-Rb
1,-Rb
2,-Rb
3,-Rc ,-mixture that monomers such as Rd are formed; Preparation component I I then obtains so-called ginseng triol group saponin, promptly mainly by panaxoside monomer-Re ,-Rf ,-Rg
1,-Rg
2,-Rg
3,-Rh
1Mixture Deng the monomer composition.As being raw material with the panax quinquefolium saponin, prepare said components I, promptly stem and leaf of Radix Panacis Quinquefolii glycol group saponin can obtain mainly by ginsenoside-Rb
2,-Rb
3,-Rc ,-mixture that monomers such as Rd are formed; Preparation component I I then obtains stem and leaf of Radix Panacis Quinquefolii triol group saponin, promptly mainly by ginsenoside-Re ,-Rg
1,-Rg
2,-PF
11,-RT
5,-F
2Mixture Deng the monomer composition.As being the feedstock production component I with the Radix Notoginseng total arasaponins, promptly so-called pseudo-ginseng Central Plains Ginsengdiol histsaponin or title Rb group (family) can obtain mainly by ginsenoside-Rb
1,-Rb
2, ,-Rd and arasaponin R
4Mixture Deng the monomer composition; Preparation component I I, the Protopanaxatriol organizes saponin or claims Rg group (family) in the promptly so-called pseudo-ginseng, then obtain mainly by ginsenoside-Re ,-Rg
1,-Rg
2, ,-Rh
1The mixture of forming with-monomers such as Rf.
Discover, Ginsengdiol histsaponin (panaxadiol saponin, PDS) have anti-mutation, Green Tea Extract, anti-oxidant and multiple function (Lin Hua etc. such as protection microbial film and cellularstructure, Ginsengdiol histsaponin is to the provide protection and the Experimental Study of Mechanism thereof of shock cell, Norman Bethune Medical University's journal, 18 (2): 123-125,1992; Lu Guang etc., Panax ginseng C.A.Meyer brings out the influence that mouse Bone marrow cells micronucleus forms, Hygiene Toxicology magazine, 4 (3): 176,1990 to endoxan; Zhao Xuejian etc., Ginsengdiol histsaponin are to the influence of endotoxin shock mouse tissue lipid peroxide, Norman Bethune Medical University's journal, 16 (4): 342,1990).Panoxatriol group saponin (panaxatriol saponin, PTS), Rg for example, then have tangible radiation resistance and promote anabolism and anti-tissue injury effect (clock state Jiangxi etc., panoxadiol and triol group saponin cause the influence of the cultivation myocardial cell action potential of damage to normal and xanthine-XOD, Acta Pharmacologica Sinica, 12 (3): 256-260,1991; Dong Yonglan etc., panoxatriol group saponin are to the preventive and therapeutic effect of x-ray bombardment rat pituitary-testis system radiotherapy damage, Chinese radiological medicine and protection magazine, 13 (5): 317,1993).
In addition, someone finds, the protopanoxadiol type saponin that extracts in the pseudo-ginseng plant (or claiming Rb group saponin) is to the electrocardiogram(ECG effect of being significantly improved of ligation coronary artery man rabbit myocardial infarction, and as seen the myocardial infarction area of medication animal dwindles to some extent, and Protopanaxatriol's type saponin (or claiming Rg group saponin) does not see that then these effects are arranged.And the analgesic effect that pseudo-ginseng Rb group and Rg organize former genseng saponin is also significantly different, and (the graceful people etc. that haves mercy on, arasaponin Rg, Rb be to the influence of myocardial ischemia, panax species academic meeting paper, in September, 89, Kunming; Wang Liwen etc., Guizhou medicine, the first phase in 1989, the 14th page).Here said protopanoxadiol type saponin and Protopanaxatriol's type saponin and sapogenin thereof are respectively protopanoxadiol and triol saponin unit (referring to the Chinese patent application No.9810 that awaits the reply jointly).Therefore, for research more in depth with develop and use the suitably biological active ingredients of part of panax species more fully, set up also and improve, and the method for separating two big components of Radix Ginseng total saponins quickly and easily is very necessary with low-cost, high yield.
[ginsenoside-Rh is produced in the preparation and the conversion thereof of 20 (S)-protopanoxadiol saponins to people such as Chen Yanping
2, Chinese Pharmaceutical Journal 32 (5): 273-275,1979] and to have reported with the panax quinquefolium saponin be raw material, utilizes organic solvent (propyl carbinol/ethyl acetate) to prepare the method for Ginsengdiol histsaponin through (nearly 12 times) extraction repeatedly.But this method is the same with the currently known methods that generally used in the past, all exists solvent load big, and some solvent (as propyl carbinol) is difficult for reclaiming, and technological operation is complicated, is unsuitable for the shortcoming of suitability for industrialized production.
Therefore, an object of the present invention is to provide a kind of total saponin with the suitable part of panax species is the method for feedstock production protopanoxadiol group and triol group saponin, this method comprises said total saponin is dissolved in the low-alcohol solution, precipitate it with alkali metal hydroxide as precipitation agent then, wait to precipitate and separate out the back and separate as the precipitation part of component I with as the supernatant part of component I I.
According to this purpose of the present invention, said preparation method further is included in the low-alcohol solution that adds the low concentration alkali metal hydroxides in the aqueous solution of component I crude extract, and with the step of strongly acidic cation-exchange purified components I.
According to this purpose of the present invention, said preparation method further is included in the component I I crude extract alcoholic solution and adds alkali metal hydroxide, and with the step of strongly acidic cation-exchange purifying obtained component II.
This purpose preferred embodiment according to the present invention, wherein said panax species suitably partly comprise root, rhizome, cauline leaf, flower and the fruit of genseng, Radix Panacis Quinquefolii and pseudo-ginseng.
This purpose preferred embodiment according to the present invention, wherein said alkali metal hydroxide comprises the oxyhydroxide of sodium and potassium, and wherein said lower alcohol comprises the monohydroxy-alcohol that contains 1-5 carbon atom.
The preferred embodiment of this purpose according to the present invention, wherein the concentration of said alkali metal hydroxide is 0.01% to 10% (W/V).
Another object of the present invention provides and mainly contains the component that protopanoxadiol group saponin and/or Protopanaxatriol organize saponin by method of the present invention preparation.
It is the pharmaceutical composition of primary activity composition with protopanoxadiol group saponin mainly that a further object of the present invention provides a kind of, said composition comprises component and one or more pharmaceutically acceptable carriers or thinner or other ancillary components by the protopanoxadiol group saponin of the inventive method preparation.Simultaneously, the present invention also provides a kind of and organizes the pharmaceutical composition that saponin is the primary activity composition with the Protopanaxatriol, the Protopanaxatriol that said composition comprises by the inventive method preparation organizes saponin and one or more pharmaceutically acceptable carriers or thinner or other ancillary components.
This purpose aspect according to the present invention, of the present inventionly organize the pharmaceutical composition that saponin is the primary activity composition with protopanoxadiol group saponin or Protopanaxatriol, except that protopanoxadiol group saponin or the Protopanaxatriol contained as the primary activity composition organize the saponin, also contain and have similar or synergistic one or more natural or other activeconstituentss of synthetic or its mixtures.
A further object of the present invention be of the present invention be the application of pharmaceutical composition in anti-mutation and Green Tea Extract oxygenizement of primary activity composition with protopanoxadiol group saponin.On the other hand, the invention still further relates to of the present invention is the application of pharmaceutical composition in Antiradiation injury of primary activity composition with Protopanaxatriol's saponin.
The total ginsenoside that the present invention relates to panax species is a raw material, separation and purifying protopanoxadiol group saponin (component I) and Protopanaxatriol organize the method for saponin mixture (component I I), with contain the pharmaceutical composition that said protopanoxadiol group saponin or Protopanaxatriol organize saponin, and their application in the human or animal's that prevention and treatment cause because of the damage of transgenation, free-radical oxidn and radiation injury pathological state respectively.
As previously mentioned, comprise in the araliaceae ginseng plant's of genseng, Radix Panacis Quinquefolii and pseudo-ginseng root, rhizome, cauline leaf, flower and the fruit and all contain abundant ginsenoside, particularly the dammarane type saponin.At present, from these plants, separate and identified multiple dammarane type four-ring triterpenoid compound, and their chemical structure, physico-chemical property and biological function carried out extensive studies.According to the migratory behaviour (Rf value) of this compounds in silica gel thin-layer chromatography (TLC), behind suitable organic solvent wash-out, total saponin can be separated into two basal components of aforementioned component I and component I I.Thereby,, and provide the basic material source for the biologic activity of these components and clinical application research for the indivedual monomers that are further purified wherein provide parent material.
Method of the present invention comprises that the total saponin with panax species is dissolved in the low-alcohol solution, the alcoholic solution that adds alkali metal hydroxide then precipitates it as precipitation agent, after treating that precipitation is separated out, separation is as the precipitation of component I part with as the supernatant part of component I I, thereby obtains the crude extract of component I and component I I respectively.The low-alcohol solution that in the crude extract aqueous solution of said component I, adds the low concentration alkali metal hydroxides then, and, obtain the purified component I with strongly acidic cation-exchange and decolouring resin anion(R.A) purifying.Add the basic metal of appropriate amount in the solution of said component I I, remove the throw out that is generated after stirring the mixture, filtrate obtains purified component I I with strongly acidic cation-exchange and decolouring resin anion(R.A) purifying.
In order to prepare the component I that is rich in protopanoxadiol group saponin and to be rich in the component I I that the Protopanaxatriol organizes saponin, at first by method well known to those skilled in the art, from panax species, as the suitable part of genseng, Radix Panacis Quinquefolii or pseudo-ginseng, as extracting Radix Ginseng total saponins in root, rhizome, cauline leaf, flower or the fruit.
With the various Radix Ginseng total saponinss that may originate is that parent material prepares ginsenoside component I and component I I., at first at room temperature total saponin is dissolved in the excessive moisture lower alcohol for this reason, filters to remove insoluble composition, obtain filtrate A with suitable filtering material.Simultaneously a certain amount of highly basic such as alkali metal hydroxide are dissolved in the least possible water, and add moisture lower alcohol therein and make alkaline alcoholic solution B, and with this solution as continue after precipitation agent in the experiment.Under the stirring at room solution B slowly is added drop-wise among the above-mentioned filtrate A, constantly has precipitation to separate out in this reaction process.Static 0.5-1 hour, separate out up to no longer including new throw out, this throw out can be filtered simply by suitable filter.Because the part relative polarity that is rich in Ginsengdiol histsaponin is bigger, and wetting ability is less relatively, therefore handle total saponin with the alkaline alcoholic solution of proper concn after, wherein mainly by-Ro ,-Rb
1,-Rb
2,-Rb
3,-Rc ,-Rd form in conjunction with the more monomer mixture of sugar, promptly be rich in the protopanoxadiol component and just at first from reaction mixture, precipitate and separate out, and mainly by-Re ,-Rg
1,-Rg
2,-Rg
3,-F
2,-Rf form in conjunction with the less monomer mixture of sugar, promptly be rich in the Protopanaxatriol and organize saponin and then still be dissolved in the said alkaline alcoholic solution.Thereby, can make to be rich in protopanoxadiol group saponin and to be rich in the Protopanaxatriol by Radix Ginseng total saponins with high yield basically and organize saponin.
According to the preferred embodiments of the invention, the parent material that is used to separate said components I and component I I better is panax quinquefolium saponin and Panax ginseng C.A.Meyer.The alcohol that is used to dissolve total saponin is the lower alcohol that contains 1-5 carbon atom, as methyl alcohol, ethanol, n-propyl alcohol, Virahol, propyl carbinol, isopropylcarbinol or amylalcohol, but ethanol preferably.Used concentration of ethanol should be greater than 85%.According to the preferred embodiments of the invention, the highly basic alcoholic solution that is used to separate total each component of saponin better is the alcoholic solution of alkali metal hydroxide, as the ethanolic soln of sodium hydroxide or potassium hydroxide.Wherein the concentration of alkali metal hydroxide generally in 0.01 to 10% (W/V) scope, is preferably 0.1 to 5%, is preferably 0.3 to 1% (W/V).The alcohol that is used to prepare precipitation agent alkali metal hydroxide alcoholic solution better is ethanol, propyl alcohol or propyl carbinol, and the ethanolic soln of preferred concentration 〉=90%.
In order to be further purified the crude extract of the ginsenoside component I of preparation as stated above, at first in the aqueous solution of gained crude extract according to about 0.05 to 5%, better the ratio of about 0.3 to 2% (W/V) adds pure alkaline solution B as indicated above, fully as seen has partly precipitated to separate out behind the mixing.Filter with the B filtration under diminished pressure or with the agglomerating glass filter then, the collecting precipitation thing, and be dissolved in water it, be added on strong acid ion exchange resin then, for example on the 101 strongly acidic cation-exchange posts, with the water elution of 3-5 times of column volume.Collect elutriant with the decolouring of decolouring resin anion(R.A), behind the water wash-out elutriant is concentrated into driedly, obtain purified ginsenoside component I, i.e. the Ginsengdiol histsaponin solids.
Equally, in order to be further purified the crude extract of the ginsenoside component I I that makes as stated above, at first according to about 0.05 to 5%, the ratio of better about 0.3 to 2% (W/V), in obtained component II crude extract, add solid alkali, for example as seen the oxyhydroxide of sodium Metal 99.5 or potassium have partly precipitated to separate out gently behind the stirring and evenly mixing.Filter with B or agglomerating glass filter then, cross the strong acid ion exchange resin post after the collection filtrate,,, collect elutriant and also decolour with the negatively charged ion decolorizing resin with the pure wash-out of 3-5 times of column volume as 101 strongly acidic cation-exchange posts.Behind pure wash-out, elutriant is concentrated into dried, obtain purified ginsenoside component I I, i.e. the solids of panoxatriol group saponin.
Because method of the present invention has been omitted complicated organic solvent (propyl carbinol/acetyl second fat) extraction step, therefore not only simplified separation-extraction technology, and saved organic solvent, greatly reduce production cost, thereby make the large-scale industrial production of genseng total packet saponin become possibility.Particularly, through laboratory scale preparation practice confirmation repeatedly, the product rate of recovery for preparing protopanoxadiol group and triol group saponin with method of the present invention is higher than the product rate of recovery of normally used organic solvent extracting taking technique in the past.
The invention further relates to a kind of pharmaceutical composition, said composition contains as the protopanoxadiol group saponin of activeconstituents or Protopanaxatriol organizes saponin and one or more pharmaceutically acceptable carrier and/or thinner, and other ancillary components.Can will be by genseng pill, solution and the suspension agent of the inventive method preparation according to known method in the pharmaceutical industry, and the sprays, creme, ointment, elixir and the suppository that are suitable for topical.
In order to prepare the solution that is suitable for the outer administration of gi tract, for example can use distilled water, water for injection, isotonic sodium chlorrde solution or glucose solution, perhaps lower concentration (for example 1-100mM) phosphate buffered saline (PBS) (PBS) is as carrier or thinner.Can add one or more other ancillary components or additives in the preparation of these gi tract external administrations, for example can use xitix as antioxidant, use Sodium Benzoate etc. are as sanitas.And in these formulations, can also contain solubilizing agent, disintegrating agent, lubricant, tinting material and dispersion agent or tensio-active agent that other are suitable for.
When preparation is suitable for the tablet, powder agent, capsule of oral administration or suppository, can use sucrose, semi-lactosi, W-Gum, gelatin, lipid, Microcrystalline Cellulose etc. as carrier or vehicle.Can use that known method and ancillary component prepare microcapsule or liposome agent in the pharmaceutical industry.
Under the situation of topical, protopanoxadiol or triol group saponin according to the inventive method preparation can be dissolved in water-bearing media or other appropriate carriers or the matrix, with above-mentioned various suitable ancillary components, mix as superoxide-dismutase free-radical scavengerss such as (SOD) and suitable skin penetrant or absorption enhancer such as dimethyl sulfoxide (DMSO) or towards the tall and erect ketone of osmanthus nitrogen, make sprays.In addition, also pharmaceutical composition of the present invention can be added in and make the Derma-Guard that emulsion, creme, lotion, facial mask, ointment etc. are made in the cosmetic industry in the known matrix.Such Derma-Guard is except that the function with conventional makeup; also have the free-radical oxidn damage of the local organization of preventing and/or treating or the function of radiotherapy damage; and skin irritation part (as face) epidermal cell proliferation; preventing the function of skin aging shrinkage, also is simultaneously the auxiliary approach of another kind of whole body administration.
Difference according to application target, in the pharmaceutical composition of the present invention except that the above-mentioned Ginsengdiol histsaponin or panoxatriol group saponin that contain as the primary activity composition, also can contain one or more other have same or similar biologic activity, have auxiliary or synergistic natural or synthetic pharmaceutical cpd or its mixture.When for example being used for antitumor purpose, can add Chinese herbal medicine extract or synthetic chemical anti-tumor drugs or their mixture at pharmaceutical composition of the present invention with auxiliary or synergistic antitumor effect.
In general, the administered intramuscular dosage of genseng group diol saponin or panoxatriol group saponin is 0.1 to 100mg/kg body weight/day in the pharmaceutical composition of the present invention, is preferably 1 to 50mg, preferably 5-30mg.The dosage of oral administration is generally 1 to 150mg/kg body weight/day, is preferably 1 to 100mg, is preferably 1 to 75mg/kg/ day.Certainly, definite consumption dosage should be determined by the clinician factors such as the susceptibility of used medicine and administering modes according to age of the character of illness to be treated or pathological state, severity, patient, body weight, patient to be treated.
Following examples are intended to further illustrate, rather than restriction the present invention.Under the prerequisite of the spirit and principles in the present invention, all will fall into the present invention and await the reply in the claim scope inventing any change that indivedual technological steps carry out and changing.
Embodiment 1
The preparation of stem and leaf of Radix Panacis Quinquefolii grouping saponin
Take by weighing panax quinquefolium saponin 100g (Dalian Tianma Pharmaceutical Co., Ltd's production), and be dissolved in the 1000ml95% ethanolic soln, slowly stir under the room temperature and make it abundant dissolving, filter with the conventional filtration device then, remove insolubles, obtain filtrate A.Careful weighing sodium hydroxide 5.0g is dissolved in the 15.0ml water, and fully the dissolving back adds 1000ml 95% ethanol in gained solution, obtains 0.5% (W/V) sodium hydroxide ethanolic soln B behind the mixing.Continue to stir down, gained alcohol sodium solution B is slowly joined among the above-mentioned filtrate A, have flocculent precipitate to generate gradually.With this mixture after under the greenhouse static 24 hours, with B or G3 funnel filtration under diminished pressure.Collect the filtrate that is deposited in the throw out on the filter plate and the suction lottle of packing into respectively, promptly obtain the crude extract of ginsenoside component I (throw out) and component I I (filtrate).
Add 100ml distilled water in said components I crude extract, heating and stirring make it abundant dissolving.In continuing stirring down, slowly add the aforesaid 0.5% sodium hydroxide alcoholic solution of 1000ml then, gained mixture room temperature was placed about 12 hours.After the glass filter vacuum filtration, the collecting precipitation thing also is dissolved in it in 400ml distilled water.This solution by 101 strongly acidic cation-exchange purifying and by the decolouring of decolouring resin anion(R.A), is used the distilled water wash-out.Above sal epsom, elutriant is evaporated to driedly, obtains purified ginsenoside component I white powder, productive rate 40.3%.Through analyzing (on silica gel g thin-layer plate, launching) with TLC, and with standard substance in contrast, prove in the products therefrom to contain-Rb with propyl carbinol/ethyl acetate/water (4: 1: 2)
2,-Rb
3,-Rc ,-Rd saponin monomer, can confirm as stem and leaf of Radix Panacis Quinquefolii glycol group saponin mixture in view of the above.
Add solid sodium hydroxide (10.0g) in the crude extract solution (2000ml) of said components II, stirring at room was placed 24 hours after 20 minutes.Filter this reaction mixture with conventional filter, disgorging, filtrate is passed through 101 strongly acidic cation-exchange posts and decolorizing resin post respectively, and uses 85% ethanol elution.Collect elutriant and under decompression, be pumped to driedly, obtain purified ginsenoside component I I powder, productive rate 34.1%.This product is carried out TLC analyzes (on silica gel g thin-layer plate, launching) and in contrast with standard substance with propyl carbinol/ethyl acetate/water (4: 1: 2), prove products therefrom mainly contain-Re ,-Rg
1,-Rg
2,-F
2The saponin monomer can confirm as stem and leaf of Radix Panacis Quinquefolii triol group saponin mixture in view of the above.
Embodiment 2
The preparation of stem and leaf of Radix Panacis Quinquefolii grouping saponin
(100g, Dalian Tianma Pharmaceutical Co., Ltd produces) is parent material with panax quinquefolium saponin, prepares component I and component I I respectively according to embodiment 1 described method basically.Different is, be dissolved in the total saponin of 100g in 1000ml 95% ethanol and after removing by filter insolubles, the concentration that slow adding prepares by method described in the embodiment 1 basically in clarifying filtrate is that the sodium hydroxide ethanolic soln of 0.2% (V/V) (is dissolved in 2.0g NaOH in the 10.0ml distilled water, add 1000ml 95% ethanol then, fully make 0.2% (W/V) NaOH-EtOH solution behind the mixing).TLC analyzes demonstration, obtained component I, and promptly the productive rate of stem and leaf of Radix Panacis Quinquefolii glycol group saponin is 33.6%; Component I I, promptly stem and leaf of Radix Panacis Quinquefolii triol group saponin (comprises anthropomorphic ginseng saponin-RF
11With-RT
5) productive rate be 35.8%.
Embodiment 3
The preparation of Stem and leaf of Radix Ginseng grouping saponin
Basically according to the method described in the embodiment 1, be parent material (100g, second pharmaceutical factory, governor white-market, Jilin produces) preparation component I and component I I with the Panax ginseng C.A.Meyer, wherein the component I productive rate is 13.0%; Component I I productive rate is 69.8%.Main component is ginsenoside-Rb in the component I after TLC analyzes (on silica gel g thin-layer plate, launching with propyl carbinol/ethyl acetate/water (4: 1: 2)) to show purification refine
1,-Rb
2,-Rc ,-Rd, so can determine that it is Stem and leaf of Radix Ginseng glycol group saponin mixture; Among the component I I then mainly by ginsenoside-Re ,-Rg
1,-Rg
2,-Rf forms, so can determine that it is Stem and leaf of Radix Ginseng triol group saponin mixture.
Embodiment 4
The preparation of Radix Notoginseng grouping saponin
Basically according to the method described in the embodiment 1, be parent material, prepare component I and component I I respectively with the total saponin of Radix Notoginseng (100g, the preparation of Norman Bethune Medical University's chemistry teaching and research room).Different is, be dissolved in the 100g Radix Notoginseng total arasaponins in 1000ml 95% ethanolic soln and after removing by filter insolubles, in the clarifying filtrate of gained, slowly add basically concentration by the preparation of method described in the embodiment 1 and be 1% sodium hydroxide ethanolic soln (in 20.0ml distilled water with the 100g dissolution of sodium hydroxide, add 1000ml 95% ethanol then, fully make 1.0% (V/V) NaOH-EtOH solution behind the mixing).TLC analyzes demonstration, obtained component I, and promptly pseudo-ginseng protopanoxadiol group saponin is mainly by ginsenoside-Rb
1,-Rb
2,-Rd and arasaponin R4 form, productive rate 38.9%; Obtained component II, promptly the pseudo-ginseng Protopanaxatriol organize saponin mainly by ginsenoside-Re ,-Rg
1,-Rg
2,-Rh
1With-the Rf composition, productive rate 41.2%.
EXPERIMENTAL EXAMPLE 1
Protopanoxadiol group saponin (PDS) is to the restraining effect of the non-program DNA of male mice sexual cell synthetic (UDS)
Bring out in methylsulphonic acid formicester (MMS, Merck Co.) in male mice (C57 BL/6J) model of the non-program DNA of sexual cell synthetic (UDS) and observe the restraining effect of PDS sexual cell UDS.Experimental result shows that MMS can induce the UDS reaction of male mice significantly.Intraperitoneal injection PDS 15mg/0.2ml before injection MMS, discovery can suppress the UDS of mouse sperm significantly, and the UDS that abdominal injection PDS (15mg/0.2ml) then brings out MMS after the MMS that comes into operation does not have obvious influence.Therefore infer that PDS can suppress the primary DNA dyssynthesis that MMS brings out, promptly PDS can stop the damage of genetic material in the mutagenic compound pair cell nuclear.
This experiment is also observed, the inhibition effect of PDS and MMS administration simultaneously is than the weak effect of the PDS that comes into operation before pre-, thereby infer that the PDS anti-DNA damnification may work indirectly by some biological procedures in the inducing cell, and may be relevant with removing free radical and the anti-oxidant activity of PDS.
EXPERIMENTAL EXAMPLE 2
The Protopanaxatriol organizes the radio-protective effect of saponin (PTS) to the male rat immune organ
Utilization is accepted the Wistar rat of x-ray bombardment (5 Gray) as experimental model, observes the influence of PTS to animal immune organ capability of resistance to radiation.Male rat is in accepting continuous 14 days of X ray full-body exposure 24 hours before and irradiation back, and abdominal injection PTS every day (5mg/0.2ml) observes the dynamic change of animal peripheral white blood cell and the change of immune organ (thymus gland and spleen) weight and cell count.The result as seen, PTS can significantly increase the peripheral white blood cell order that is subjected to the x-ray bombardment rat, stops the lethal effect of ray to animal thymus and spleen cell.It can also be seen that from control group gained data PTS can improve the peripheral white blood cell order of normal rat and the cell number of thymus gland and spleen tissue.
The above results prompting, the Protopanaxatriol organizes saponin and can stop the marrow korocyte that suffers the radiotherapy damage animal to reduce, but then not remarkable to the provide protection of fully-developed leucocytes reduction.Thereby proving further that PTS mainly acts on is to stimulate the marrow hemopoiesis tissue, suppresses and/or repairs the damage of ray to hemopoietic tissue, and then promote the recovery of hemopoietic function and the release of eukocyte.In addition, The above results is also pointed out, and PTS can protect immune organ, makes it to alleviate the damage that causes because of radiation, thereby improves body's immunological function.
Claims (10)
1. the total saponin with the suitable part of panax species is the method for feedstock production protopanoxadiol group and triol group saponin, this method comprises said total saponin is dissolved in the low-alcohol solution, precipitate it with alkali metal hydroxide as precipitation agent then, wait to precipitate and separate out the back and separate as the precipitation part of component I with as the supernatant part of component I I.
2. according to the method for claim, said preparation method further is included in the low-alcohol solution that adds the low concentration alkali metal hydroxides in the aqueous solution of component I crude extract, and with the step of strongly acidic cation-exchange purified components I.
3. according to the method for claim, said preparation method further is included in the component I I crude extract alcoholic solution and adds alkali metal hydroxide, and with the step of strongly acidic cation-exchange purifying obtained component II.
4. according to any one method in the claim 1 to 3, wherein said panax species suitably part comprises root, rhizome, cauline leaf, flower and the fruit of genseng, Radix Panacis Quinquefolii and pseudo-ginseng.
5. according to any one method in the claim 1 to 3, wherein said alkali metal hydroxide comprises the oxyhydroxide of sodium and potassium, and wherein said lower alcohol comprises the monohydroxy-alcohol that contains 1-5 carbon atom.
6. according to any one method in the claim 1 to 5, wherein the concentration of said alkali metal hydroxide is 0.01% to 10% (W/V).
7. according to the protopanoxadiol group saponin of the method preparation of any one in the claim 1 to 5.
8. the Protopanaxatriol according to the method preparation of any one in the claim 1 to 5 organizes saponin.
9. pharmaceutical composition, said composition comprises by the component of the protopanoxadiol group saponin of each method preparation or component and one or more pharmaceutically acceptable carriers or thinner or other ancillary components that the Protopanaxatriol organizes saponin in the claim 1 to 6.
10. according to the pharmaceutical composition of claim 9, said pharmaceutical composition also contains and has similar or synergistic one or more natural or other activeconstituentss of synthetic or its mixtures.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98100070 CN1061986C (en) | 1998-01-22 | 1998-01-22 | Preparation, medicinal composition and application of grouped gensenoside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98100070 CN1061986C (en) | 1998-01-22 | 1998-01-22 | Preparation, medicinal composition and application of grouped gensenoside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1190098A true CN1190098A (en) | 1998-08-12 |
| CN1061986C CN1061986C (en) | 2001-02-14 |
Family
ID=5215784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98100070 Expired - Lifetime CN1061986C (en) | 1998-01-22 | 1998-01-22 | Preparation, medicinal composition and application of grouped gensenoside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1061986C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092204C (en) * | 1998-07-28 | 2002-10-09 | 吉林大学基础医学院科技开发中心 | Semisynthesizing method for 20(S)-ginsenoside Rg3, and use in medicine |
| CN1092203C (en) * | 1998-07-22 | 2002-10-09 | 北京鑫利恒医药科技发展有限公司 | Process for extracting ginsenoside Re, and use of medicine thereof |
| WO2003040383A1 (en) * | 2001-11-06 | 2003-05-15 | Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences | Preparation of 20-$g(b)-d-pyranoglucosyl-protopanaxadiol by enzymatic hydrolysis of ginsenoside |
| CN100563668C (en) * | 2003-08-18 | 2009-12-02 | 株式会社柳柳 | Use the gen-seng and the processing thereof of vinegar |
| CN100594910C (en) * | 2004-06-03 | 2010-03-24 | 昆明香格喜玛生物技术有限责任公司 | Compound panoxatriol saponin with physiological activity and its preparation and use |
| CN101121743B (en) * | 2000-11-15 | 2011-05-11 | 山东绿叶天然药物研究开发有限公司 | Process for extracting anticancer product from natural plant |
| CN1869058B (en) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | Method of preparing trialcohol group ginseng saponine and bialcohol group ginseng saponine from notoginseng |
| CN1869057B (en) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | Preparation method of trialcohol group ginseng saponine and bialcohol group ginseng saponine |
| CN1869059B (en) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | Method of preparing ginseng saponine monomer from ginseng leaf |
| CN1869048B (en) * | 2006-06-21 | 2012-10-03 | 海南亚洲制药有限公司 | Method of extracting and separating F group ginseng saponin from ginseng leaf |
| CN106589040A (en) * | 2016-12-28 | 2017-04-26 | 芜湖艾森格生物技术有限公司 | Method for separating panaxtrol saponin Rg1 and Re from panaxadiol saponin |
-
1998
- 1998-01-22 CN CN 98100070 patent/CN1061986C/en not_active Expired - Lifetime
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092203C (en) * | 1998-07-22 | 2002-10-09 | 北京鑫利恒医药科技发展有限公司 | Process for extracting ginsenoside Re, and use of medicine thereof |
| CN1092204C (en) * | 1998-07-28 | 2002-10-09 | 吉林大学基础医学院科技开发中心 | Semisynthesizing method for 20(S)-ginsenoside Rg3, and use in medicine |
| CN101121743B (en) * | 2000-11-15 | 2011-05-11 | 山东绿叶天然药物研究开发有限公司 | Process for extracting anticancer product from natural plant |
| WO2003040383A1 (en) * | 2001-11-06 | 2003-05-15 | Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences | Preparation of 20-$g(b)-d-pyranoglucosyl-protopanaxadiol by enzymatic hydrolysis of ginsenoside |
| CN100563668C (en) * | 2003-08-18 | 2009-12-02 | 株式会社柳柳 | Use the gen-seng and the processing thereof of vinegar |
| CN100594910C (en) * | 2004-06-03 | 2010-03-24 | 昆明香格喜玛生物技术有限责任公司 | Compound panoxatriol saponin with physiological activity and its preparation and use |
| CN1869058B (en) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | Method of preparing trialcohol group ginseng saponine and bialcohol group ginseng saponine from notoginseng |
| CN1869057B (en) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | Preparation method of trialcohol group ginseng saponine and bialcohol group ginseng saponine |
| CN1869059B (en) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | Method of preparing ginseng saponine monomer from ginseng leaf |
| CN1869048B (en) * | 2006-06-21 | 2012-10-03 | 海南亚洲制药有限公司 | Method of extracting and separating F group ginseng saponin from ginseng leaf |
| CN106589040A (en) * | 2016-12-28 | 2017-04-26 | 芜湖艾森格生物技术有限公司 | Method for separating panaxtrol saponin Rg1 and Re from panaxadiol saponin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1061986C (en) | 2001-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101122786B1 (en) | Method for preparing a Centella asiatica extract rich in madecassoside and in terminoloside | |
| CN1061986C (en) | Preparation, medicinal composition and application of grouped gensenoside | |
| CN101323635B (en) | Panax notoginseng saponins ST-4, and medicinal composition, preparation and use thereof | |
| CN1833692B (en) | False portulaca oleracea extracts, its prepn. and usage | |
| WO2010032269A2 (en) | Anti-inflammatory activity of the iridoid glycosides | |
| CN1210289C (en) | Radde anemone rhizome extract and its prepn process and use | |
| CN107929544B (en) | Preparation method and application of mileanine part and monomer in bletilla plants | |
| CN1411466A (en) | Compound (I), method for extracting it and pharmaceutical composition containing it | |
| CN111454317B (en) | Panaxadiol type triterpenoid saponin, folium Notoginseng extract, pharmaceutical composition and cosmetic composition with antiinflammatory activity | |
| CN1091448C (en) | Method for preparing 20(S)-ginsenoside-RH2, medicinal compositions therewith and use thereof | |
| CN108524668B (en) | Preparation method of Chinese wolfberry extract with repairing and treating effects on drug-induced liver injury | |
| CN101007035B (en) | Application of notoginseng glycol saponins for treating memory deterioration | |
| CN101220063B (en) | Novel method for preparing catalpol, medicament composition containing the same and uses thereof | |
| CN101322734B (en) | Codonopsis lanceolata total saponins with anti-inflammatory immunity function and preparation thereof | |
| CN113666804A (en) | Fermented gastrodia elata extract with anti-depression activity and preparation and application thereof | |
| CN112618560A (en) | Pharmaceutical composition containing ginsenoside and application thereof in reducing blood fat and inhibiting fatty liver | |
| CN104840451B (en) | It is a kind of for treating coronary heart disease, the effective ingredient in Chinese of hyperlipidemia, preparation method and the therefrom method of separating effective ingredient | |
| CN110204589B (en) | Effective component of feather cockscomb seed, extraction method and application thereof in preparing neuroprotective medicament | |
| CN1488355A (en) | Cough-relieving chinese medicine formulation of total glycoside of mango leaf | |
| CN1244334C (en) | Novel use of traditional Chinese medicine rabdosia rubeseens and Isodon longitubus | |
| KR101237898B1 (en) | A composition having anti-metastatic effect | |
| CN102977177B (en) | Triterpenoid saponin class anti-myocardial ischemia chemical compound extracted from clematis tangutica | |
| CN111187330B (en) | Triterpenoid saponin component with anti-photodamage activity in folium Notoginseng | |
| CN1187352A (en) | Medicine composition of saponin containing protopanaxyndiol component and preparing process and application thereof | |
| CN113444136B (en) | Preparation of anti-breast cancer type B cardiac glycoside and application thereof in resisting liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20010214 |
|
| CX01 | Expiry of patent term |